



Annex to Decision GB/11/2025

Selection process for the members of the Global Health EDCTP3 Stakeholders Group

1. For the purpose of selecting the organisations to be represented in the Stakeholders Group, a transparent Call for Expressions of Interest (hereinafter referred to as "CoEI") is to be launched.
2. The CoEI is to be launched by the Executive Director of the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3). He/she must ensure that the process laid down in this Governing Board Decision and the specific criteria required for the organisations to be represented are duly taken into account in the CoEI. The Executive Director shall oversee the overall process under the authority of the Governing Board.
3. The CoEI should be drafted in such a way as to guarantee the ultimate provision of relevant advice from the advisory group to anchor Global Health EDCTP3's work in the global health context and to safeguard the principles of ensuring a balanced representation in terms of:
 - Stakeholders' thematic expertise and interests represented, ensuring representativity of the SRIA thematic areas;
 - Sector (public institutions/industry/academia/civil society/patients' representatives/private sector);
 - Geographical distribution (balance between Europe and sub-Saharan Africa (SSA); regional balance within SSA);
 - Other relevant principles as required.
4. Additional expertise or skills required that are relevant to the objectives and tasks of Global Health EDCTP3, as set out in Articles 99 and 100 of the Regulation, should be reflected in the CoEI and the subsequent selection process. The same applies to any exclusion/eligibility criteria for membership of the Stakeholders Group.
5. The CoEI is to be published on the website of Global Health EDCTP3 and in such other publications as necessary to ensure the widest possible openness, including sector specific.
6. Following the deadline of the CoEI, the Executive Director will prepare a list of all candidate organisations eligible to be represented in the Stakeholders Group based on the essential criteria referred to below.
7. The list of eligible candidate organisations will be proposed to an evaluation panel appointed by the Executive Director, composed of four members (two representatives from the European Commission and two representatives from the EDCTP Association), who will carry out an objective assessment of the eligible candidates on the basis of all the specific selection criteria set out below. The panel must include people with adequate expertise and that are free of conflicts of interest, in addition to being gender balanced. The outcome of the evaluation will be to establish a shortlist of up to 30 organisations. The shortlist will only include those organisations deemed best suited for appointment. In addition to this shortlist, the evaluation panel will also draw up a reserve list with up to 20 organisations.
8. The Executive Director will present the conclusions of the evaluation panel to the Governing Board. The Governing Board is also to be informed of:
 - The organisations not included in the shortlist/reserve list; and
 - The list of the organisations already excluded by the Executive Director in his/her initial selection.



9. The Governing Board will appoint the stakeholders based on the shortlist. The Governing Board will also approve the reserve list based on the proposal of the evaluation panel. Any deviation from the proposals of the evaluation panel must be justified.
10. The term of appointment of the organisations represented in the Stakeholders Group shall be two years. Renewal for a maximum of two additional years shall be possible. Renewal should be based on a decision of the Governing Board acting on a proposal by the Executive Director.
11. The reserve list approved by the Governing Board should, in principle, be valid for the term of appointment (including renewal) of the organisations represented in the Stakeholders Group. The reserve list serves the purpose of replacing organisations that (during their term) stop, for whichever reason, being represented in the Stakeholders Group. Appointees from the reserve list should only serve for the remaining term (including renewal) of the organisation they replace. Appointment of an organisation on the reserve list should only be possible if the latter continues to satisfy the eligibility criteria in this Governing Board Decision.
12. Where justified and in limited cases, the Governing Board may appoint organisations in the Stakeholders Group directly, without basing its decision on the outcome of a selection by way of a CoEI.
13. Selected organisations must appoint a representative and an alternate that would have to meet the criteria set out below. The representative and the alternate must be approved by the Executive Director, who checks that they meet the criteria. Selected organisations may request to change their representatives and alternates where justified. Representatives and alternates need to leave the Stakeholder Group as soon as they quit their organisation.

Selection criteria

1. The essential criteria for representatives and alternates are:
 - (a) At least ten years of professional experience in the field as defined in the SRIA (as per Annex I).
 - (b) Very good command of written and spoken English.
 - (c) Proven experience of participation in advisory bodies.
- The composition of the Stakeholders Group must be gender balanced. The Executive Director shall therefore take this requirement into account before approving the representatives proposed by the organisations selected to be represented in the Stakeholders Group.
2. The evaluation criteria for organisations represented are:

Expertise, activity or representation of interests in at least one of the following areas:

 - Patient organisations;
 - Civil society in global health, in particular as regards infectious diseases in sub-Saharan Africa;
 - Professional international and regional organisations active in the areas of global health, especially infectious diseases in sub-Saharan Africa in alignment with the scope of the SRIA;
 - Local or regional government representatives providing health services in sub-Saharan Africa and addressing infectious diseases;
 - Social entrepreneurs and product development partnerships developing solutions for issues in global health, especially infectious diseases in sub-Saharan Africa;
 - Businesses/industry/SMEs working in the area of global health, especially infectious diseases in sub-Saharan Africa;
 - Research institutions addressing infectious diseases affecting sub-Saharan Africa;



Global Health
EDCTP3

Co-funded by
the European Union



- Other funders of global health research with a focus on low- and middle-income countries.

3. In its assessment, the Governing Board shall take into account:

- (a) The competences, expertise and representativeness that are necessary to provide input on the scientific, strategic and technological priorities to be addressed by Global Health EDCTP3, and identify synergies with other programmes and funders
- (b) The need to reflect balanced stakeholder representation from a geographic, thematic and gender perspective, including in particular sub-Saharan African expertise. As far as possible, the Global Health EDCTP3 Stakeholders Group should be balanced in terms of North-South representation with preference for European and sub-Saharan African stakeholders.

4. Persons who are employed by a member of Global Health EDCTP3 or its constituent entities or staff (including external staff) of Global Health EDCTP3 shall not be eligible. This includes all EU institutions, agencies and bodies.



Annex I. Global Health EDCTP3 SRIA thematic mapping

Diseases	Research / environment	Countermeasures	Collaboration
Main themes			
HIV	Clinical trials	Diagnostics	North-North; North-South; South-South collaboration
TB	Clinical research	Preventive tools	Networks of excellence
Malaria	Clinical evaluation	Vaccines	Regional networks
Neglected infectious diseases	Research capacity	Treatments	
Diarrheal diseases	Capacity building	Regulatory capacity	
Lower respiratory tract infections	Product-focused implementation studies	Innovation	
(re)-emerging infectious diseases	Implementation research		
Climate crisis-related infectious diseases	Epidemiological studies		
Antimicrobial resistance	Institutional infrastructure development		
Drug resistant infections	Epidemiologist training		
NCDs	Ethics capacity		
Poverty-related IDs			
Secondary themes			
Co-infections		Late-stage products development	
Co-morbidities		Product development partnership	
Ebola		Novel drug treatment and formulations	
Lassa fever			
Yellow fever			
Marburg			
SARS-CoV-2			
Overarching themes			
Evidence based decision making			
Individual, social, economic burden			
Health security			
Environmental change			
Climate crisis			
Access to care			
SDG3			
Vulnerable populations			